Use of Modified Functional Assays for Activated Protein C Resistance in Patients with Basally Prolonged aPTT

Summary

Inherited resistance to activated protein C (APCr) is currently recognized as the most prevalent cause underlying venous thrombophilia, with an estimated prevalence around 20% in thrombotic patients and around 1.8-7% in the general population. A correct laboratory diagnosis of APCr is therefore essential. Two different diagnostic approaches are at present at our disposal: the semi-quantitative plasma test based on the measurement of two aPTTs (in the presence and absence of activated protein C), and the detection of the factor V Arg⁵⁰⁶ GIn mutation by DNA analysis.

In this study we firstly evaluated sensitivity, specificity and diagnostic efficiency of an aPTT-based plasma clotting test (Chromogenix, Sweden) versus DNA analysis; then, since the APC resistance test is invalidated by a basally prolonged aPTT (i.e. during warfarin and heparin therapy or in patients with clotting factor deficiencies or in the presence of a lupus anticoagulant), patient plasmas were conveniently diluted in factor V deficient plasma in order to correct clotting factor abnormalities. Nevertheless, patients with a LA and an aPTT ratio range 1.8-3.17 were still all misclassified. We obtained correct diagnoses in LA positive patients by preincubating plasmas with a mixture of phospholipids; therefore we decided to perform a double modified clotting test adding a mixture of platelet derived phospholipids to samples previously diluted in factor V deficient plasma. The performance characteristics of this novel method with a different aPTT reagent (Behring, Germany) were also evaluated. With this double modified test all patients were correctly classified as negative or positive for factor V mutation in agreement with DNA analysis, irrespectfully of the basal aPTT value and the aPTT reagent employed. We propose this modified version of the APCr clotting test as an easily reproducible, reliable, very sensitive and specific screening test which possibly reduces the need for DNA analysis.

• References

• 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 2 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism. N Engl J Med 1994; 330: 517-522
• 3 Dahlbäck B. New molecular insights into genetic thrombophilia. Resistance to activated protein C caused by Arg⁵⁰⁶ to Gin mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-1348
• 4 De StefanoV, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, Clinical Syndromes and management. Blood 1996; 87: 3531-3544
• 5 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De RondeH, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 6 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point mutation at Arg⁵⁰⁶ of factor V. Lancet 1994; 343: 1535-1536
• 7 Ress DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134
• 8 Mannucci PM. Frequency of factor V Arg⁵⁰⁶ Gin in Italians. Thromb Haemost 1996; 75: 694
• 9 Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-1035
• 10 Zöller B, Bemtsdatter A, Garcia de FrutosP, Dahlbäck B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523
• 11 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conrad J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-421
• 12 Bokarewa MI, Bremme K, Blombäck M. Arg⁵⁰⁶-Gln mutation in factor V and risk of thrombosis during pregnancy. Brit J Haematol 1996; 92: 473-478
• 13 Rintelen C, Mannhalter C, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in female homozygous for factor V Leiden. Brit J Haematol 1996; 93: 487-490
• 14 De Ronde H, Bertina RM. Laboratory diagnosis of APC resistance: A critical evaluation of the test and development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
• 15 Dahlbäck B. Resistance to activated protein C, the Arg⁵⁰⁶ to Gin mutation in the factor V gene and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-742
• 16 Gschwandtner ME, Lechner K, Pabinger I. Erroneously low APC ratio in patients with lupus anticoagulant. Am J Heamtol 1995; 70: 169-170
• 17 Halbmayer WM, Haushofer A, Shön R, Fisher M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost 1994; 72: 645-646
• 18 Jorquera JL, Montero JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 334: 1162-1163
• 19 Trossaërt M, Conrad J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709
• 20 Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-733
• 21 Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 01-31
• 22 Martorell JR, Muñoz-Castillo A, Gil JL. False positive activated protein C resistance due to antiphospholipid antibodies is corrected by platelet extract. Thromb Haemost 1995; 74: 796-797
• 23 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for diagnosis of lupus anticoagulant: an update. On behalf of the Subcommittee on lupus anticoagulant/antiphospholipid antibody of the Scientific and Standardisation Committee of the ISTH. Thomb Haemost 1995; 74: 1185-1190
• 24 Triplett DA, Brandt JT, Kaczor D, Schaffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
• 25 Zöller B, Svensson PJ, HE X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Inv 1994; 94: 2521-2524